Trial · NCT05802212
Effect of Metformin on Patients With Polycystic Ovary Syndrome
NCT05802212, Not applicable, Completed, Peking University Third Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Metformin on Patients With Polycystic Ovary Syndrome. Trials, record NCT05802212. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05802212
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Metformin on Patients With Polycystic Ovary Syndrome
- NCT number
- NCT05802212
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 77 participants, actual
- Lead sponsor
- Peking University Third Hospital
- Conditions
- PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries
- Interventions
- Metformin intervention for 12 weeks
- First posted
- 2023-04-06
- Last updated
- 2025-11-25
Source ClinicalTrials.gov
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Luteinizing hormone in serum | before and after 2, 12 weeks of intervention | Changes of luteinizing hormone(mIU/mL) in serum after the intervention. |
| Primary | 4-Androstenedione in serum | before and after 2, 12 weeks of intervention | Changes of 4-Androstenedione(pmol/L) in serum after the intervention. |
| Secondary | Testosterone in serum | before and after 2, 12 weeks of intervention | Changes of testosterone(nmol/L) in serum after the intervention. |
| Secondary | Estradiol in serum | before and after 2, 12 weeks of intervention | Changes of estradiol(pmol/L) in serum after the intervention. |
| Secondary | Prolactin in serum | before and after 2, 12 weeks of intervention | Changes of prolactin(ng/mL) in serum after the intervention. |
| Secondary | Follicle number | after 12 weeks of intervention | The number of all antral follicles in each ovary will be determined using transvaginal ultrasonography for each participant. |
| Secondary | Follicle number | before intervention | The number of all antral follicles in each ovary will be determined using transvaginal ultrasonography for each participant. |
| Secondary | Ovarian volume | after 12 weeks of intervention | The size of each ovary will be determined using transvaginal ultrasonography for each participant in early follicular phase. |
| Secondary | Ovarian volume | before intervention | The size of each ovary will be determined using transvaginal ultrasonography for each participant in early follicular phase. |
| Secondary | The alterations of plasma lipid metabolites | after 12 weeks of intervention | Determination the alterations of lipid metabolites before and after metformin intervention by metabolomics. |
1 to 10 of 19Source ClinicalTrials.gov
See all 19 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05802212
GET https://conductscience.org/api/trials/v1/NCT05802212/registered